Thursday 10 September 2026

One To Watch

D3 Bio

A Chinese, clinical-stage biotechnology company developing new medicines in oncology and immunology.

The company's lead candidate is D3S-001, a next-generation KRAS G12C inhibitor designed to enhance clinical outcomes by improving KRAS G12C target engagement. As of Q2 2024, D3S-001 is in the global Phase II development stage.

Want to Update your Company's Profile?


Latest D3 Bio News

D3 Bio bags $108 million in Series B financing
10 December 2025
$40 million investment for Chinese drug developer
8 April 2024
Big build-up for D3 Bio, a Chinese biotech launched with $200 million Series A financing
17 November 2020
More D3 Bio news >


Today's issue

US generic and biosimilar meds save $496B in just 1 year
Generics
US generic and biosimilar meds save $496B in just 1 year
10 September 2026
Biotechnology
NICE backs Darzalex-based quadruplet for newly-diagnosed myeloma, J&J's second blood cancer win in a week
10 September 2026
Biotechnology
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
10 September 2026
Biotechnology
Evommune's EVO756 misses primary endpoint in atopic dermatitis Phase IIb
10 September 2026
Biotechnology
FDA accepts Roche’s Enspryng sBLA for MOGAD
10 September 2026
Biotechnology
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
10 September 2026
Biotechnology
Alchemab Therapeutics expands leadership team
10 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze